BCBS Arkansas

Does BCBS Arkansas cover Zepbound?

Quick answer · Weight Loss

BCBS Arkansas covers Zepbound for weight loss with prior authorization on Employer / Commercial Insurance and ACA Marketplace.

  • Employer / Commercial Insurance: Covered with requirements. BMI of 30 or higher
  • ACA Marketplace: Covered with requirements. BMI of 30 or higher

Last verified June 2, 2026. Source: 6192-C_Zepbound.pdf. How we verify this data →

Check your card for your exact plan →

Zepbound for Weight Loss

What BCBS Arkansas requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, T2DM, and dyslipidemia)
  • 6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Obesity (BMI >= 30)

All of:

  • Adult patient (18+)
  • Participated in a comprehensive weight management program with behavioral modification, reduced-calorie diet, and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
  • Baseline BMI >= 30 kg/m2
  • Used with a reduced-calorie diet and increased physical activity

Overweight with comorbidity (BMI >= 27)

All of:

  • Adult patient (18+)
  • Participated in a comprehensive weight management program with behavioral modification, reduced-calorie diet, and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
  • Baseline BMI >= 27 kg/m2
  • Used with a reduced-calorie diet and increased physical activity

Plus any one of:

  • Hypertension
  • Type 2 diabetes mellitus
  • Dyslipidemia

Documentation to bring

  • Baseline BMI documentation (>= 30 kg/m2 OR >= 27 kg/m2 with comorbidity; if transitioning from another weight loss drug, baseline BMI at start of any drug therapy)
  • Documentation of at least one weight-related comorbid condition if baseline BMI is >= 27 and < 30 kg/m2 (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia)
  • Documentation of participation in a comprehensive weight management program (behavioral modification, reduced-calorie diet, increased physical activity with continuing follow-up) for at least 6 months prior to drug therapy

Quantity limits

  • 2.5mg/0.5mL, 5mg/0.5mL, 7.5mg/0.5mL, 10mg/0.5mL, 12.5mg/0.5mL, 15mg/0.5mL — 2 mL (4 pre-filled single-dose pens) / 21 days; 6 mL (12 pre-filled single-dose pens) / 63 days (84-day)
  • 2.5mg/0.6mL, 5mg/0.6mL, 7.5mg/0.6mL, 10mg/0.6mL, 12.5mg/0.6mL, 15mg/0.6mL — 2.4 mL (1 single-patient-use KwikPen) / 21 days; 7.2 mL (3 single-patient-use KwikPens) / 63 days (84-day)

Approval and renewal

  • Initial approval: 8 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, Patient must have completed at least 3 months of therapy at a stable maintenance dose AND lost at least 5% of baseline body weight OR continued to maintain their initial 5% weight loss. BMI and lifestyle program requirements are not re-verified at continuation, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Coadministration with other tirzepatide-containing products is not recommended
  • Coadministration with any GLP-1 receptor agonist is not recommended
  • Vials are excluded (covered under LillyDirect manufacturer program)
  • OTC products are not included

Policy note: Baseline BMI is defined as BMI at the start of any drug therapy when patient is transitioning from another weight loss medication. The 28-day fill period uses 21-day supply and the 84-day fill period uses 63-day supply to allow time for refill processing.

verified June 2, 2026 · source: 6192-C_Zepbound.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • BMI of 27 or higher with a weight-related condition (HTN, T2DM, and dyslipidemia)
  • 6 months of a documented diet and exercise program

Qualification pathways

You can qualify through any one of these.

Obesity (BMI >= 30)

All of:

  • Adult patient (18+)
  • Participated in a comprehensive weight management program with behavioral modification, reduced-calorie diet, and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
  • Baseline BMI >= 30 kg/m2
  • Used with a reduced-calorie diet and increased physical activity

Overweight with comorbidity (BMI >= 27)

All of:

  • Adult patient (18+)
  • Participated in a comprehensive weight management program with behavioral modification, reduced-calorie diet, and increased physical activity with continuing follow-up for at least 6 months prior to drug therapy
  • Baseline BMI >= 27 kg/m2
  • Used with a reduced-calorie diet and increased physical activity

Plus any one of:

  • Hypertension
  • Type 2 diabetes mellitus
  • Dyslipidemia

Documentation to bring

  • Baseline BMI documentation (>= 30 kg/m2 OR >= 27 kg/m2 with comorbidity; if transitioning from another weight loss drug, baseline BMI at start of any drug therapy)
  • Documentation of at least one weight-related comorbid condition if baseline BMI is >= 27 and < 30 kg/m2 (e.g., hypertension, type 2 diabetes mellitus, dyslipidemia)
  • Documentation of participation in a comprehensive weight management program (behavioral modification, reduced-calorie diet, increased physical activity with continuing follow-up) for at least 6 months prior to drug therapy

Quantity limits

  • 2.5mg/0.5mL, 5mg/0.5mL, 7.5mg/0.5mL, 10mg/0.5mL, 12.5mg/0.5mL, 15mg/0.5mL — 2 mL (4 pre-filled single-dose pens) / 21 days; 6 mL (12 pre-filled single-dose pens) / 63 days (84-day)
  • 2.5mg/0.6mL, 5mg/0.6mL, 7.5mg/0.6mL, 10mg/0.6mL, 12.5mg/0.6mL, 15mg/0.6mL — 2.4 mL (1 single-patient-use KwikPen) / 21 days; 7.2 mL (3 single-patient-use KwikPens) / 63 days (84-day)

Approval and renewal

  • Initial approval: 8 months
  • Renewal: every 12 months
  • To renew, the plan looks for at least 5% weight loss from the starting weight, Patient must have completed at least 3 months of therapy at a stable maintenance dose AND lost at least 5% of baseline body weight OR continued to maintain their initial 5% weight loss. BMI and lifestyle program requirements are not re-verified at continuation, and at least 12 weeks on therapy before the first renewal. Make sure your starting weight and date are in the chart now — renewal is measured against it.

Not covered when

  • Coadministration with other tirzepatide-containing products is not recommended
  • Coadministration with any GLP-1 receptor agonist is not recommended
  • Vials are excluded (covered under LillyDirect manufacturer program)
  • OTC products are not included

Policy note: Baseline BMI is defined as BMI at the start of any drug therapy when patient is transitioning from another weight loss medication. The 28-day fill period uses 21-day supply and the 84-day fill period uses 63-day supply to allow time for refill processing.

verified June 2, 2026 · source: 6192-C_Zepbound.pdf

Zepbound for Osa

What BCBS Arkansas requires, by plan type. Open this indication on its own page →

Employer / Commercial Insurance

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

Moderate to severe OSA with obesity

All of:

  • Adult patient (18+)
  • Established diagnosis of moderate to severe OSA with AHI >= 15 events per hour on polysomnography (PSG) or home sleep apnea test (HSAT) with a technically adequate device
  • Current BMI >= 30 kg/m2
  • Used with a reduced-calorie diet and increased physical activity

Documentation to bring

  • Documentation of established diagnosis of moderate to severe OSA with AHI >= 15 events per hour on polysomnography (PSG) or home sleep apnea test (HSAT) with a technically adequate device
  • Current BMI documentation (>= 30 kg/m2)

Quantity limits

  • 2.5mg/0.5mL, 5mg/0.5mL, 7.5mg/0.5mL, 10mg/0.5mL, 12.5mg/0.5mL, 15mg/0.5mL — 2 mL (4 pre-filled single-dose pens) / 21 days; 6 mL (12 pre-filled single-dose pens) / 63 days (84-day)
  • 2.5mg/0.6mL, 5mg/0.6mL, 7.5mg/0.6mL, 10mg/0.6mL, 12.5mg/0.6mL, 15mg/0.6mL — 2.4 mL (1 single-patient-use KwikPen) / 21 days; 7.2 mL (3 single-patient-use KwikPens) / 63 days (84-day)

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • To renew, the plan looks for Patient must demonstrate a positive response to treatment from baseline evidenced by a decrease in OSA symptoms, and must be treated with a maintenance dosage based on individual treatment response and tolerability. OSA diagnosis (AHI >= 15) must be re-documented at continuation.

Not covered when

  • Coadministration with other tirzepatide-containing products is not recommended
  • Coadministration with any GLP-1 receptor agonist is not recommended
  • Vials are excluded (covered under LillyDirect manufacturer program)
  • OTC products are not included

Policy note: OSA must be moderate to severe (AHI >= 15 events/hour). No PAP/CPAP trial requirement is stated. Continuation requires documented decrease in OSA symptoms and treatment at a maintenance dose. The 28-day fill period uses 21-day supply and the 84-day fill period uses 63-day supply to allow time for refill processing.

verified June 2, 2026 · source: 6192-C_Zepbound.pdf

ACA Marketplace

Covered with requirements

What you need to qualify

  • Age 18 and older
  • BMI of 30 or higher
  • Diagnosed obstructive sleep apnea (AHI of 15 or higher)

Qualification pathways

You can qualify through any one of these.

Moderate to severe OSA with obesity

All of:

  • Adult patient (18+)
  • Established diagnosis of moderate to severe OSA with AHI >= 15 events per hour on polysomnography (PSG) or home sleep apnea test (HSAT) with a technically adequate device
  • Current BMI >= 30 kg/m2
  • Used with a reduced-calorie diet and increased physical activity

Documentation to bring

  • Documentation of established diagnosis of moderate to severe OSA with AHI >= 15 events per hour on polysomnography (PSG) or home sleep apnea test (HSAT) with a technically adequate device
  • Current BMI documentation (>= 30 kg/m2)

Quantity limits

  • 2.5mg/0.5mL, 5mg/0.5mL, 7.5mg/0.5mL, 10mg/0.5mL, 12.5mg/0.5mL, 15mg/0.5mL — 2 mL (4 pre-filled single-dose pens) / 21 days; 6 mL (12 pre-filled single-dose pens) / 63 days (84-day)
  • 2.5mg/0.6mL, 5mg/0.6mL, 7.5mg/0.6mL, 10mg/0.6mL, 12.5mg/0.6mL, 15mg/0.6mL — 2.4 mL (1 single-patient-use KwikPen) / 21 days; 7.2 mL (3 single-patient-use KwikPens) / 63 days (84-day)

Approval and renewal

  • Initial approval: 6 months
  • Renewal: every 12 months
  • To renew, the plan looks for Patient must demonstrate a positive response to treatment from baseline evidenced by a decrease in OSA symptoms, and must be treated with a maintenance dosage based on individual treatment response and tolerability. OSA diagnosis (AHI >= 15) must be re-documented at continuation.

Not covered when

  • Coadministration with other tirzepatide-containing products is not recommended
  • Coadministration with any GLP-1 receptor agonist is not recommended
  • Vials are excluded (covered under LillyDirect manufacturer program)
  • OTC products are not included

Policy note: OSA must be moderate to severe (AHI >= 15 events/hour). No PAP/CPAP trial requirement is stated. Continuation requires documented decrease in OSA symptoms and treatment at a maintenance dose. The 28-day fill period uses 21-day supply and the 84-day fill period uses 63-day supply to allow time for refill processing.

verified June 2, 2026 · source: 6192-C_Zepbound.pdf

Why Zepbound requests get denied by BCBS Arkansas

Based on what this policy asks for. Fix these before the first submission.

  1. Wrong brand for the diagnosis. Zepbound and Mounjaro are the same molecule with different approved uses; a request for Zepbound under a diagnosis that matches Mounjaro is routinely denied.
  2. BMI not documented in the chart notes (or documented without a baseline weight and date).
  3. Qualifying weight-related condition not documented with its own diagnosis code.
  4. No documented diet and exercise program.
  5. Baseline weight wasn't recorded at the start, so the required weight loss can't be shown at renewal.

Frequently asked questions

Does BCBS Arkansas cover Zepbound?
BCBS Arkansas covers Zepbound for weight loss with prior authorization on Employer / Commercial Insurance and ACA Marketplace.
What BMI do you need for Zepbound under BCBS Arkansas?
For weight loss on Employer / Commercial Insurance plans, BCBS Arkansas requires a BMI of 30 or higher, or 27 or higher with a qualifying weight-related condition. Other plan types may differ — see each plan type below.
How long does a Zepbound approval last with BCBS Arkansas?
Initial approvals last 8 months, and renewals are granted in 12-month periods.
What does BCBS Arkansas require to renew Zepbound?
At least 5% weight loss from the starting weight, Patient must have completed at least 3 months of therapy at a stable maintenance dose AND lost at least 5% of baseline body weight OR continued to maintain their initial 5% weight loss. BMI and lifestyle program requirements are not re-verified at continuation, and at least 12 weeks on therapy before the first renewal.
How current is this information?
This page reflects BCBS Arkansas's written policy as of its current version, last verified against the source document on June 2, 2026.

Other medications under BCBS Arkansas

Zepbound coverage under other plans

All insurance plans · All medications

This page summarizes BCBS Arkansas's written prior-authorization policy. It is not a guarantee of coverage; plans vary by employer and benefit design. Verify with your plan before relying on it.